1402883-61-7

Basic information

• Product Name: 2-amino-6-((1S,2R)-2-(3′-(cyclopropylmethoxy)biphenyl-4-yl)-cyclopropyl)-3-methylpyrimidin-4(3H)-one hydrochloride
• Synonyms: 2-amino-6-((1S,2R)-2-(3′-(cyclopropylmethoxy)biphenyl-4-yl)-cyclopropyl)-3-methylpyrimidin-4(3H)-one hydrochloride
• CAS NO: 1402883-61-7
• Molecular Weight: 423.942
• Mol File: 1402883-61-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-amino-6-((1S,2R)-2-(3′-(cyclopropylmethoxy)biphenyl-4-yl)-cyclopropyl)-3-methylpyrimidin-4(3H)-one hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-6-((1S,2R)-2-(3′-(cyclopropylmethoxy)biphenyl-4-yl)-cyclopropyl)-3-methylpyrimidin-4(3H)-one hydrochloride(1402883-61-7)
• EPA Substance Registry System: 2-amino-6-((1S,2R)-2-(3′-(cyclopropylmethoxy)biphenyl-4-yl)-cyclopropyl)-3-methylpyrimidin-4(3H)-one hydrochloride(1402883-61-7)

Safety Data

• Hazardous Substances Data: 1402883-61-7(Hazardous Substances Data)

Upstream product

• 1402883-95-7 C₂₀H₂₂BrN₃O₅ 
• 1402884-01-8 2-bis(tert-butoxycarbonyl)amino-3-methyl-6-[(1S,2R)-2-(3-bromophenyl)cyclopropyl]pyrimidin-4(3H)-one 
• 411229-76-0 (3-(cyclopropylmethoxy)phenyl)boronic acid 
• 1402883-87-7 (1R,2S)-1-(4-bromophenyl)-2-(3-ethoxy-3-oxopropanoyl)cyclopropanecarboxylic acid 
• 1402883-98-0 (1R,2S)-2-(2-(bis(tert-butoxycarbonyl)amino)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-1-(4-bromophenyl)-cyclopropanecarboxylic acid 
• 1402883-92-4 (1R,2S)-methyl 2-(2-(bis(tert-butoxycarbonyl)amino)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-1-(4-bromophenyl)cyclopropanecarboxylate 
• 1402883-89-9 (1R,2S)-methyl 2-(2-amino-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-1-(4-bromophenyl)cyclopropanecarboxylate 

Relevant articles and documents

Conformational restriction approach to β-Secretase (BACE1) inhibitors: Effect of a cyclopropane ring to induce an alternative binding mode

Improvement of a drugs binding activity using the conformational restriction approach with sp3 hybridized carbon is becoming a key strategy in drug discovery. We applied this approach to BACE1 inhibitors and designed four stereoisomeric cyclopropane compounds in which the ethylene linker of a known amidine-type inhibitor 2 was replaced with chiral cyclopropane rings. The synthesis and biologic evaluation of these compounds revealed that the cis-(1S,2R) isomer 6 exhibited the most potent BACE1 inhibitory activity among them. X-ray structure analysis of the complex of 6 and BACE1 revealed that its unique binding mode is due to the apparent CH-π interaction between the rigid cyclopropane ring and the Tyr71 side chain. A derivatization study using 6 as a lead molecule led to the development of highly potent inhibitors in which the structure-activity relationship as well as the binding mode of the compounds clearly differ from those of known amidine-type inhibitors.